Ultrasound-self-splitting IL-12 polymer vesicle for tumor immunotherapy and preparation method of ultrasound-self-splitting IL-12 polymer vesicle

Ultrasonic-self-cleaved IL-12 polymer vesicles formed by self-assembly of β-amino ester random copolymer solve the problem of inefficient current IL-12 delivery methods and achieve IL-12 accuracy under ultrasound mediation The effect of release and tumor immunotherapy has improved, and the safety and effectiveness of cancer treatment have been improved.

CN118948769APending Publication Date: 2024-11-15SHANGHAI UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411063889.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing IL-12 delivery methods are inefficient and cannot achieve accurate and controllable release, resulting in serious side effects of high-dose treatment, limiting its clinical application in cancer treatment, and the effect of deep tumor treatment is poor.

Method used

Ultrasonic-self-cleaved IL-12 polymer vesicles formed by self-assembly of β-amino ester random copolymer, coated with the sound-sensitizers Ce6 and interleukin-12, inducing polymer self-cleavage by ultrasound mediating the production of ROS Release IL-12, enhance immune response, and coordinate the treatment of tumors.

Benefits of technology

The safe and precise release of IL-12 mediated by ultrasound is achieved, the efficacy and safety of tumor immunotherapy is improved, the antigen-specific T cell amplification and tumor cell killing effect is enhanced, and systemic toxicity is reduced.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948769A_ABST
    Figure CN118948769A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of anti-tumor immunity, and discloses an ultrasound-self-splitting IL-12 polymer nano-vesicle and a preparation method thereof. The ultrasound-self-splitting IL-12 polymer nano-vesicle is a polymer vesicle which is formed by self-assembling a beta-amino ester random copolymer containing an ROS responsive group and is coated with a sound-sensitive agent and IL-12, efficient loading of IL-12 is successfully achieved, immunogenic death of tumor cells can be induced in vitro under ultrasound mediation, and the tumor cells can be efficiently loaded. The maturation of BMDC cells is effectively stimulated, and the expression level of co-stimulatory molecules on the surfaces of the BMDC cells is improved; the polypeptide can activate CD8 < + > and CD4 < + > T lymphocytes at the same time in vivo, safe amplification of antigen-specific effector T cells is achieved, besides, infiltration of immune cells such as CD8 < + > cytotoxic T lymphocytes, natural killer T cells and natural killer NK cells in tumor tissue can be increased, the T cells and the NK cells are stimulated to generate interferon-gamma, a good tumor cell killing effect is achieved, and the polypeptide can be applied to tumor treatment. The synergistic anti-tumor effect of sonodynamic combined immunotherapy is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of nanomaterials and immunotherapy, and in particular to an ultrasound-self-cleaving IL-12 polymer nanovesicle coated with a sonosensitizer Ce6 and a cytokine IL-12 and a preparation method thereof. Background Art

[0002] Tumor immunotherapy is a new type of therapy that uses the body's own immune system to identify, attack and destroy tumor cells. It has the advantages of high specificity, durability, low side effects, wide applicability and potential for personalized treatment. It mainly includes bacterial immunotherapy, monoclonal antibody therapy, immune checkpoint inhibitor therapy, adoptive cell immunotherapy, oncolytic virus therapy, tumor vaccines and cytokine therapy. Among them, cytokine therapy has become a hot topic in the field of cancer immunotherapy due to its advantages in stimulating the immune system, enhancing T cell activity and improving immune memory, as well as its application potential in different types of cancer. Among cytokines, several interleukins are particularly relevant to the treatment of cancer. Compared with other interleukins, IL-12 is a very powerful immunostimulant that can stimulate and enhance the activity of T cells, natural killer cells and macrophages. It helps to increase the number and effectiveness of these immune cells, thereby strengthening the immune system's attack on cancer cells. At the same time, IL-12 can also promote Th1 (helper T cell 1, Th1) immune response and improve immune memory. In addition, IL-12 can also be used in combination with other immunotherapies (such as immune checkpoint inhibitors) or traditional treatments (such as chemotherapy or radiotherapy) to improve the efficacy of cancer treatment. Although IL-12 has potential in cancer treatment, it still faces some challenges in its application. For example, high-dose IL-12 treatment may be accompanied by serious side effects, including fever, hypotension, immunosuppression, and organ damage, which reduce the safety of treatment and limit its clinical application. In addition, IL-12 needs to be delivered locally to the tumor to reduce its damage to normal tissues during systemic treatment. Therefore, it is urgent to develop a safe and effective delivery method to ensure that IL-12 can accurately target the target area. At present, there are three general methods for IL-12 delivery strategies: the first involves the fusion of the targeting part with IL-12; the second method is to deliver the genetic material encoding IL-12 directly to the tumor or target tissue; the third method is that the delivery system is directly injected or implanted into the tumor or tissue to achieve local sustained release of recombinant IL-12 protein. Compared with systemic delivery, local delivery enhances the centralized distribution of IL-12 in the disease area and reduces the toxic side effects on normal tissues.

[0003] In 2022, the Yash Agarwal research group in the United States combined the phosphoserine residues of IL-12 with the hydroxyl groups on the surface of the common vaccine aluminum hydroxide adjuvant through a ligand exchange reaction. After local injection, the endogenous responsive release of IL-12 to the pH of the tumor tissue was achieved, so that it has a high enrichment in the tumor tissue, promotes immune activity, and significantly inhibits tumor growth. Although other biomaterials, such as lipid nanoparticles, have also been explored for local delivery, the current delivery methods are inefficient and cannot achieve precise and controllable release of IL-12. Unlike endogenous responsive delivery platforms, exogenous response (such as light, ultrasound, magnetism, and heat) delivery systems are more precise, efficient, and controllable. Among them, external field ultrasound response carriers have more advantages in controlling drug release and enrichment in deep tumor tissues. Challenges in the production and scalability of delivery systems also lead to continued obstacles to the clinical application of IL-12.

[0004] Sonodynamic therapy (SDT) is a new treatment method that uses the interaction between ultrasound and specific sonosensitizers to treat diseases. It uses ultrasound to stimulate sonosensitizers to release reactive oxygen species (ROS), thereby destroying diseased tissues. Due to its excellent tissue penetration, it has great potential as a treatment for deep tumors. However, in clinical applications, the reactive oxygen species generated by ultrasound are not enough to completely regress tumors, and sonodynamic therapy may require multiple courses of treatment to achieve the desired therapeutic effect. Summary of the invention

[0005] In view of this, the present invention combines the cutting-edge achievements in the field of cancer immunotherapy and sonodynamic therapy to provide an ultrasound-self-cleaving IL-12 polymer vesicle for tumor immunotherapy and a preparation method thereof, using β-amino ester random copolymer (PBAE TK ) is amphiphilic and self-assembles to encapsulate the sonosensitizer chlorin-e6 (Ce6) and interleukin-12 (IL-12) to form polymer vesicles (PBAE) TK @Ce6@IL-12, P TK CI), under ultrasound-mediated, the ROS produced induces tumor ICD effect and causes PBAE TK It self-cleaves and releases IL-12 to amplify antigen-specific T cells and enhance the body's immune response to achieve the effect of synergistic tumor treatment and improve the efficacy and safety of IL-12 cancer immunotherapy.

[0006] The purpose of the present invention is achieved through the following technical solutions:

[0007] The present invention first provides an ultrasound-self-cleaving IL-12 polymer nanovesicle, which is a polymer vesicle coated with a sonosensitizer and interleukin-12 formed by self-assembly of a β-amino ester random copolymer, wherein the β-amino ester random copolymer is an amphiphilic polymer containing a ROS responsive group, wherein the ROS responsive group is a thioketal unit, and the sonosensitizer is dihydrochlorin e6.

[0008] Specifically, the mass ratio of the β-amino ester random copolymer to interleukin-12 is 5000:1 to 10000:1, and the mass ratio of the β-amino ester random copolymer to the sonosensitizer is 15:1 to 40:1.

[0009] Specifically, the size of the polymer vesicles is 100-200 nm.

[0010] Specifically, the β-amino ester random copolymer is composed of NH 2 -PEG-NH 2 Obtained by addition reaction with diacrylate monomers.

[0011] In a specific embodiment, the diacrylate monomer is 7,7-dimethyl-4,10-dioxo-3,11-dioxa-6,8-dithiotridecane-1,13-diacrylate.

[0012] The present invention also provides a method for preparing the above-mentioned ultrasound-self-cleaving IL-12 polymer vesicles, comprising mixing the β-amino ester random copolymer and dihydrochlorin e6 in dimethyl sulfoxide, and then adding the mixture to a phosphate buffer containing interleukin-12 to form polymer vesicles in a self-assembly manner, thereby obtaining ultrasound-self-cleaving IL-12 polymer vesicles.

[0013] Specifically, the preparation method is: the β-amino ester random copolymer and dihydrochlorin e6 are mixed in dimethyl sulfoxide by vortexing, and then the mixed solution of the β-amino ester random copolymer and dihydrochlorin e6 is slowly pumped into a phosphate buffer containing interleukin-12 by a peristaltic pump using a nano-microemulsion method, and the mixture is placed on a magnetic stirrer and stirred for a certain period of time, and then dialyzed overnight to obtain ultrasound-self-cleaving IL-12 polymer vesicles.

[0014] Specifically, the peristaltic pump has a peristaltic speed of 0.1 mL / min, the magnetic stirrer has a stirring time of 12 h to 24 h, and a stirring speed of 1000 rpm / min.

[0015] Specifically, the mixing mass ratio of the β-amino ester random copolymer to dihydrochlorin e6 is 10:1 to 5:1, and the mixing mass ratio of the β-amino ester random copolymer to interleukin-12 is 5000:1 to 10000:1.

[0016] In a specific embodiment, the mixing mass ratio of the β-amino ester random copolymer, dihydrochlorin e6 and interleukin-12 is 10000:1000:1, and every 5 mg of β-amino ester random copolymer corresponds to 50 μg of interleukin-12, 1-2 mL of DMSO and 3-5 mL of phosphate buffer.

[0017] The present invention also provides the use of the ultrasound-self-cleavage IL-12 polymer vesicles in the preparation of tumor therapeutic drugs.

[0018] The present invention has the following beneficial effects:

[0019] (1) The ultrasound-self-cleaving IL-12 polymer vesicles provided by the present invention have an interleukin loading rate of over 90%. Under ultrasound mediation, reactive oxygen species (ROS) are generated, the polymer self-cleaves, and the release of IL-12 is controlled. The cytokine IL-12 can be safely delivered and accurately released, avoiding the systemic toxicity of IL-12.

[0020] (2) The ultrasound-self-cleaving IL-12 polymer vesicles provided by the present invention simultaneously produce ROS-induced tumor cell ICD effect under ultrasound mediation, which can effectively recruit innate immune cells at the injection site and achieve safe expansion of antigen-specific effector T cells. In addition, it can also increase the number of CD8 + The infiltration of immune cells such as cytotoxic T lymphocytes and natural killer cells can achieve a good tumor cell killing effect by stimulating T cells and NK cells to produce interferon-γ (IFN-γ), thereby exerting the synergistic anti-tumor effect of sonodynamic combined with immunotherapy. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 PBAE prepared in Preparation Example 3 TK @Ce6(P TK C) TEM characterization image;

[0022] Figure 2 PBAE prepared in Example 1 TK @Ce6@IL-12(P TK CI) TEM characterization image;

[0023] Figure 3 P prepared in Example 1 TK TEM characterization image after CI ultrasound;

[0024] Figure 4 PBAE prepared in Comparative Example 1 44N @Ce6@IL-12(P 44N CI) and P prepared in Example 1TK Quantitative graphs of Ce6 and IL-12 loading rates in CI;

[0025] Figure 5 P prepared in Example 1 TK UV absorption curves of CI and methylene blue (MB) at different ultrasound times;

[0026] Figure 6 P prepared in Example 1 TK UV absorption curves of CI and 1,3-diphenylisobenzofuran (DPBF) at different ultrasound times;

[0027] Figure 7 P prepared in Preparation Example 3 TK C is a graph showing the survival rate of TC-1 tumor cells after co-incubation with TC-1 tumor cells at different concentrations for 24 hours without ultrasound or with ultrasound treatment;

[0028] Figure 8 PBAE prepared in Preparation Example 1 TK (P TK ), PBAE prepared in Preparation Example 2 44N (P 44N ), P prepared in Preparation Example 3 TK C. PBAE prepared in Preparation Example 4 44N @Ce6(P 44N C) Analysis of the survival rate of TC-1 tumor cells without or with ultrasound after co-incubation with TC-1 tumor cells for 12 hours;

[0029] Fig. 9 PBAE prepared in Preparation Example 1 TK (P TK ), PBAE prepared in Preparation Example 2 44N (P 44N ), P prepared in Preparation Example 3 TK C. PBAE prepared in Preparation Example 4 44N @Ce6(P 44N C) Quantitative analysis of mean fluorescence intensity of ROS production after co-incubation with TC-1 tumor cells under ultrasound or without ultrasound treatment;

[0030] Fig.10 PBAE prepared in Preparation Example 1 TK (P TK ), PBAE prepared in Preparation Example 2 44N (P 44N ), P prepared in Preparation Example 3 TK C. PBAE prepared in Preparation Example 4 44N @Ce6(P 44NC) Quantitative analysis of DC maturation detected after the supernatant of TC-1 tumor cells was co-incubated with BMDCs for 20 h, including the expression of CD80 and CD86;

[0031] Fig.11 P prepared in Preparation Example 1 TK , P prepared in Preparation Example 3 TK C. PBAE prepared in Comparative Example 1 44N @Ce6@IL-12(P 44N CI) and P prepared in Example 1 TK Antigen-specific CD8 induced by CI in the TC-1 tumor model + Quantitative analysis of IFN-γ produced by T cells;

[0032] Fig.12 P prepared in Preparation Example 1 TK , P prepared in Preparation Example 3 TK C. P prepared in Comparative Example 1 44N CI and P prepared in Example 1 TK Antigen-specific CD4 induced by CI in the TC-1 tumor model + Quantitative analysis of IFN-γ produced by T cells;

[0033] Fig.13 P prepared in Preparation Example 1 TK , P prepared in Preparation Example 3 TK C. P prepared in Comparative Example 1 44N CI and P prepared in Example 1 TK Antigen-specific CD4 induced by CI in the TC-1 tumor model + Quantitative analysis of effector T cells;

[0034] Fig.14 P prepared in Preparation Example 1 TK , P prepared in Preparation Example 3 TK C. P prepared in Comparative Example 1 44N CI and P prepared in Example 1 TK CD8 in tumor tissue induced by CI in TC-1 tumor model + Quantitative analysis of T cell infiltration;

[0035] Fig.15 P prepared in Preparation Example 1 TK , P prepared in Preparation Example 3 TK C. P prepared in Comparative Example 1 44N CI and P prepared in Example 1 TK Quantitative analysis of NKT cells in tumor tissues induced by CI in the TC-1 tumor model;

[0036] Fig.16 P prepared in Preparation Example 1 TK , P prepared in Preparation Example 3 TK C. P prepared in Comparative Example 1 44N CI and P prepared in Example 1 TK Quantitative analysis of NK cells in tumor tissues induced by CI in the TC-1 tumor model;

[0037] Fig.17 Schematic diagram of the working principle of the ultrasound-self-cleaving IL-12 polymer vesicles of the present invention for tumor immunotherapy. DETAILED DESCRIPTION

[0038] In order to better explain the present invention, the present invention is described in detail with reference to the embodiments of the present invention, and the main contents of the present invention are further illustrated in conjunction with specific examples, but the content of the present invention is not limited to the following examples. If no specific technology or conditions are indicated in the examples, the technology or conditions described in the literature in this area or the product instructions are used. If the manufacturer of the reagents or instruments is not indicated, they are all conventional products that can be obtained commercially.

[0039] The present invention is further described in detail below through examples and related performance tests.

[0040] Preparation Example 1 PBAE TK Polymer (P TK )

[0041] Specifically prepared by the following steps:

[0042] 0.6 mL of 7,7-dimethyl-4,10-dioxo-3,11-dioxa-6,8-dithiotridecane-1,13-diacrylate solution was added to 1 mL of 0.5 M NH 2 -PEG-NH 2 The solution (dissolved in dimethyl sulfoxide) was placed on a shaker for 24 hours at a shaking speed of 220 rpm / min and a temperature of 28°C. After dialysis, a β-amino ester random copolymer PBAE containing thioketal repeating units was obtained. TK (denoted as P TK ).

[0043] Preparation Example 2PBAE 44N Polymer (P 44N )

[0044] Specifically prepared by the following steps:

[0045] 2.02 mmol 1,4-butanediol diacrylate and 1.84 mmol 4-amino-1-butanol were dissolved in dimethyl sulfoxide, and heated and stirred in an oil bath for 24 hours at 90°C and 600 rpm / min to obtain a mixture. 0.6 mL of the above mixture was added to 1 mL of 0.5 M NH 2 -PEG-NH 2 The solution (dissolved in dimethyl sulfoxide) was placed on a magnetic stirrer and stirred for 24 hours at a stirring speed of 1000 rpm / min. After dialysis, a control polymer PBAE without thioketal was obtained. 44N (denoted as P 44N ).

[0046] Preparation Example 3P TK Preparation of C nanoparticles

[0047] Specifically prepared by the following steps:

[0048] 5 mg of polymer PBAE TK 0.5 mg of sonosensitizer Ce6 was dissolved in 1.5 mL of dimethyl sulfoxide and vortexed to obtain a mixed solution. The mixed solution was then pumped into 4 mL of water by a peristaltic pump and stirred on a magnetic stirrer for 24 hours at a stirring speed of 1000 rpm / min. P was then obtained by dialysis. TK C.

[0049] Preparation Example 4P 44N Preparation of C nanoparticles

[0050] Specifically prepared by the following steps:

[0051] 5 mg of polymer PBAE 44N The sonosensitizer Ce6 was dissolved in 1.5 mL of dimethyl sulfoxide and vortexed to obtain a mixed solution. The mixed solution was then pumped into 4 mL of water by a peristaltic pump and stirred on a magnetic stirrer for 24 hours at a stirring speed of 1000 rpm / min. P was then obtained by dialysis. 44N C.

[0052] Example 1P TK Preparation of CI nanovesicles

[0053] Specifically prepared by the following steps:

[0054] 50 μg of IL-12 was dissolved in 4 mL of phosphate buffer solution to obtain IL-12 solution; 5 mg of polymer PBAE TK0.5 mg of sonosensitizer Ce6 was dissolved in 1.5 mL of dimethyl sulfoxide (DMSO) and mixed to obtain a mixed solution; the mixed solution was then pumped into the IL-12 solution by a peristaltic pump and stirred on a magnetic stirrer for 24 hours at a stirring speed of 1000 rpm / min. Ultrasound-self-cleaved IL-12 polymer vesicles (denoted as P) were obtained by dialysis. TK CI).

[0055] Comparative Example 1P 44N Preparation of CI nanovesicles

[0056] Specifically prepared by the following steps:

[0057] 50 μg of IL-12 was dissolved in 4 mL of phosphate buffer solution to obtain IL-12 solution; 5 mg of polymer PBAE 44N and sonosensitizer Ce6 were dissolved in 1.5 mL of dimethyl sulfoxide and mixed to obtain a mixed solution; the mixed solution was then pumped into the IL-12 solution by a peristaltic pump and stirred on a magnetic stirrer for 24 hours at a stirring speed of 1000 rpm / min, and then dialyzed to obtain a control IL-12 polymer vesicle (denoted as P 44N CI).

[0058] <Performance Test>

[0059] 1. Transmission Electron Microscopy

[0060] Take a small amount of P prepared in Preparation Example 3 TK C. P prepared in Example 1 TK After CI and ultrasound (ultrasound conditions: 1MHz, 1.5W / cm 2 ,50%duty cycle) TK CI nanoparticles were dissolved in 1 mL of water, and 10 μL of each was dripped onto the copper grid of the transmission electron microscope. After ten minutes, the droplets were dried with filter paper, and then 10 μL of 1% wt uranyl acetate dye was dripped. After ten minutes, the droplets were dried with filter paper for TEM morphology photography. The test results are shown in Figure 2. Figure 1-3 shown.

[0061] Result analysis: Figure 1-2 As shown, transmission electron microscopy showed that P TK C and P TK CIs all have folded vesicle structures and are evenly dispersed. TK The particle size of C is about 400nm, P TK The particle size of CI is about 200nm. Figure 3 As shown, under ultrasonic irradiation, P TK The self-destructive disassembly of CI vesicles into small fragments proves that PBAE TKPolymer vesicles are ultrasound responsive.

[0062] 2. UV spectrophotometer to measure the loading rate

[0063] Take a small amount of commercial Ce6 and IL-12 purchased and dissolve them in appropriate amounts of DMSO and water to prepare stock solutions, then dilute the stock solutions in gradients to prepare working solutions of different concentrations, transfer each working solution to a quartz cuvette, place it in an ultraviolet spectrophotometer to detect the absorbance values ​​at the characteristic absorption peaks of Ce6 (at 404nm) and IL-12 (at 672nm), and make standard curves of Ce6 and IL-12 based on the linear equation of concentration and absorbance. 44N CI and P prepared in Example 1 TK CI nanovesicle solution was dissolved in DMSO and water, respectively, and the above solutions were transferred to quartz cuvettes, respectively, and placed in a UV spectrophotometer to detect the absorbance at 404nm and 672nm, respectively. The absorbance values ​​were substituted into the standard curve equations of the corresponding substances, and the concentrations of Ce6 and IL-12 were calculated. According to the feed weight of Ce6 and IL-12, the respective loading rates were calculated. The test results are shown in Figure 2. Figure 4 As shown:

[0064] Result analysis: Figure 4 As shown, the prepared P 44N CI and P TK The loading rates of Ce6 in CI nanovesicles were 13.97% and 28.90%, respectively; the loading rates of IL-12 were 96.90% and 96.00%, respectively.

[0065] 3. In vitro ROS assay

[0066] (1) The P prepared in Example 1 TK CI (1 mg / mL) was mixed with methylene blue (MB, 1 μg / mL) in 2 mL DMSO. The mixture was then subjected to ultrasound (US) treatment at different time points, including 0, 1, 2, 4, and 8 minutes. The working solution after ultrasound treatment was evaluated on a UV-visible absorption spectrometer at 662 nm for the generation of ·OH.

[0067] (2) Prepare P from Example 1 TK CI (1 mg / mL) was mixed with 1,3-diphenylisobenzofuran (DPBF, 100 μM / mL) in 2 mL of DMSO. To reduce the decomposition of DPBF, the mixture was then sonicated for different time points in a dark environment, including 0, 1, 2, 4, and 8 minutes. The working solution after sonication was evaluated on a UV-visible absorption spectrometer at 416 nm. 1 O2 Generation of.

[0068] Result analysis: Figure 5 As shown, in P TK In the presence of CI, as the ultrasonic time increases, MB reacts with the generated ·OH, resulting in a significant decrease in the characteristic absorption at 662 nm, indicating that P TK CI has the ability to generate ·OH in vitro under ultrasound and the in vitro ·OH generation is ultrasound time-dependent. Figure 6 As shown, in P TK In the presence of CI, as the US time increases, DPBF and the generated 1 O 2 The reaction resulted in a significant decrease in the characteristic absorption at 416 nm, indicating that P TK CI has extracorporeal ultrasound generation 1 O 2 ability and in vitro 1 O 2 The generation is ultrasound time dependent.

[0069] 4. Tumor cell safety and lethality assay

[0070] (1) TC-1 tumor cells were inoculated into two 96-well plates, one for subsequent ultrasonic treatment and the other without ultrasonic treatment. After the cells adhered to the wall, appropriate amounts of P prepared in Preparation Example 3 were added to the two 96-well plates. TK C (where Ce6 concentration was 10 μg / mL), at 37°C, 5% CO 2 After continuous incubation in the cell culture incubator for 8 hours, the ultrasound group was subjected to ultrasound treatment, and the ultrasound conditions were set as follows: 1.5W, 50% duty cycle, 5min. The ultrasound and non-sound groups were incubated for another 8 hours, and then 10% CCK8 reagent was added. After further incubation for 50 minutes, the absorbance at 450nm was detected by an enzyme marker. The test results are shown in Figure 7 shown.

[0071] (2) TC-1 tumor cells were inoculated in two 96-well plates, one for subsequent ultrasonic treatment and the other without ultrasonic treatment. After the cells adhered to the wall, PBS (negative control) was added to the two 96-well plates respectively, and the P prepared in Example 1 was added to the two 96-well plates. TK , P prepared in Preparation Example 2 44N , P prepared in Preparation Example 3 TK C, P prepared in Preparation Example 4 44N C (where P TK C.P 44N The Ce6 concentration in the C material group was 10 μg / mL) and the samples were heated at 37°C and 5% CO 2After continuous incubation for 8 hours in a cell culture incubator, the ultrasound group was subjected to ultrasound, and the ultrasound conditions were set as follows: 1.5W, 50% duty cycle, 5min. After ultrasound and the non-ultrasound group, they were incubated for another 8 hours, and then 10% CCK8 reagent was added. After further incubation for 50 minutes, the absorbance at 450nm was detected by an enzyme marker. The test results are shown in Figure 8 shown.

[0072] Result analysis: Figure 7 It can be seen that different concentrations of P TK C had good cell safety without ultrasound. After ultrasound treatment, different concentrations of P TK C all had different degrees of TC-1 tumor cell killing effects. Figure 8 It can be seen that when no ultrasound was used, all groups had good cell safety. After ultrasound treatment, the P TK C has the most significant killing effect on TC-1 tumor cells.

[0073] 5. ROS generation in tumor cells

[0074] TC-1 cells were cultured at 2×10 5 / mL density was inoculated in a 6-well plate, and after the cells adhered to the wall, PBS (negative control) was added, and the P prepared in Example 1 was TK , P prepared in Preparation Example 2 44N , P prepared in Preparation Example 3 TK C, P prepared in Preparation Example 4 44N C (where P TK C.P 44N The Ce6 concentration in the C material group was 10 μg / mL) for subsequent ultrasonic treatment, and 5 groups without ultrasonic treatment were set up in parallel. 2 After continuous incubation in a cell culture incubator for 8 hours, one of the plates was ultrasonically treated, and the ultrasonic conditions were set to: 1.5W, 50% duty cycle, 5min. DCFH-DA (FITC channel) was used as a probe to detect ROS levels. An appropriate amount of probe was incubated with the cell culture medium for 45 minutes, and then digested with trypsin. After terminating the digestion, it was transferred to a flow tube and centrifuged at 350g for 5 minutes at 4°C to collect the cell pellet. After blowing with PBS once, it was centrifuged again under the same conditions to obtain the cell pellet, and finally resuspended in 250μL FACS Buffer for flow cytometry detection.

[0075] Result analysis: Fig. 9 As shown, P TK , P 44N C and P TKC can generate ROS of different intensities under ultrasonic treatment, among which P TK The mean fluorescence intensity of ROS produced by C was the most significant.

[0076] 6.ICD induces BMDC maturation in vitro

[0077] TC-1 cells were cultured at 2×10 5 / mL density was inoculated in a 6-well plate, and after the cells adhered to the wall, PBS (negative control) was added, and the P prepared in Example 1 was TK , P prepared in Preparation Example 2 44N , P prepared in Preparation Example 3 TK C, P prepared in Preparation Example 4 44N C (where P TK C.P 44N The Ce6 concentration in the C material group was 10 μg / mL) for subsequent ultrasonic treatment, and 5 groups without ultrasonic treatment were set up in parallel. 2 The cells were incubated in a cell culture incubator for 8 hours and then sonicated. The sonication conditions were set to: 1.5W, 50% duty cycle, 5 min. The cells were incubated for 24 hours. The supernatant was collected by centrifugation.

[0078] BMDCs were cultured at 5 × 10 5 The cells were inoculated at a density of 100 μL / mL in flow cytometry tubes, and 100 μL of the supernatant collected after the above tumor cell treatment was added to each tube. The cells were incubated at 37°C and 5% CO 2 The cells were incubated in a cell culture incubator for 20 hours. After the incubation, the cells were centrifuged and washed to obtain cell pellets. The cell pellets were stained with antibodies and analyzed by flow cytometry.

[0079] Result analysis: Fig.10 As shown, P TK C can significantly induce BMDC maturation after ultrasound.

[0080] 5. Assessing Antigen-specific T Cells in Vivo

[0081] 6-8 week old C57BL / 6J mice were inoculated with 2×10 5 TC-1 tumor cells (day 0), when the tumor size reaches 50 mm 3 When the dose of Ce6 was 5 mg / kg and the dose of IL-12 was 110 μg / kg, 50 μL PBS (negative control) and the P prepared in Preparation Example 1 were injected respectively. TK , P prepared in Preparation Example 3 TK C. P prepared in Comparative Example 1 44N CI and P prepared in Example 1 TKCI, among which, for PBS group and P TK CI was divided into two groups: the non-ultrasound group and the PBS group. TK , P TK C.P 44N CI, P TK CI also set up ultrasound groups, a total of 7 groups. The ultrasound groups were treated 12 hours after the injection of the materials. The ultrasound conditions were set as: 1.5W, 50% duty cycle, 5min.

[0082] When the tumor size of the PBS group reaches 1500mm 3 The experiment was terminated at 14:00 pm, and the spleens of mice in all groups were collected and analyzed by flow cytometry after a series of treatments including mincing, digestion, centrifugation, staining, and fixation.

[0083] Result analysis: Fig.11 , 12 As shown in 13, P TK CI can significantly induce E7 antigen-specific CD8 in the spleen after ultrasound + IFN-γ + T cells and CD4 + IFN-γ + T cell percentage, and also significantly upregulates antigen-specific CD4 + The number of effector T cells was confirmed by ultrasound-mediated P TK CI can induce antigen-specific effector T cell immune responses.

[0084] 6. Immune cell infiltration in tumor tissue

[0085] 6-8 week old C57BL / 6J mice were inoculated with 2×10 5 TC-1 tumor cells (day 0), when the tumor size reaches 50 mm 3 At the time of the experiment, 50 μL of PBS (negative control) and the P prepared in Preparation Example 1 were injected at a dose of Ce6 = 5 mg / kg and IL-12 = 110 μg / kg. TK , P prepared in Preparation Example 3 TK C. P prepared in Comparative Example 1 44N CI and P prepared in Example 1 TK CI, among which, for PBS group and P TK CI was divided into two groups: the non-ultrasound group and the PBS group. TK , P TK C.P 44N CI, P TKCI also set up ultrasound groups, a total of 7 groups. The ultrasound groups were treated 12 hours after the injection of the materials. The ultrasound conditions were set as: 1.5W, 50% duty cycle, 5min.

[0086] When the tumor size of the PBS group reaches 1500mm 3 The experiment was terminated at 14:00 pm, and the tumor tissues of all groups of mice were collected. After a series of treatments including mincing, digestion, centrifugation, staining, and fixation, flow cytometry analysis was performed.

[0087] Result analysis: Fig.14 , 15 As shown in 16, P TK CI can significantly promote CD3 + CD8 + T cells in the tumor, and can also significantly upregulate the proportion of NKT cells and NK cells in the tumor, proving that ultrasound-mediated P TK CI can induce infiltration of effector cells in vivo and achieve efficient anti-tumor immune response.

[0088] In summary, if Fig.17 As shown, the ultrasound-self-cleaving IL-12 polymer vesicles of the present invention can generate reactive oxygen species (ROS) under ultrasound mediation, and the polymer self-cleaves to control the release of IL-12, which can safely deliver and accurately release the cytokine IL-12 and avoid the systemic toxicity of IL-12; it can induce the immunogenic cell death (ICD) of tumor cells in vitro, effectively stimulate the maturation of mouse bone marrow-derived dendritic cells (BMDC), and increase the expression level of costimulatory molecules on their surface; it can simultaneously activate CD8 + and CD4 + T lymphocytes, achieving safe expansion of antigen-specific effector T cells, and also increasing CD8 + The infiltration of immune cells such as cytotoxic T lymphocytes, natural killer T cells (NKT cells), and natural killer T cells (NK) cells can achieve a good tumor cell killing effect by stimulating T cells and NK cells to produce interferon-γ (IFN-γ), thereby exerting the synergistic anti-tumor effect of sonodynamic combined with immunotherapy.

[0089] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any form. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be regarded as the protection scope of the present invention.

Claims

1. An ultrasound-self-cleaving IL-12 polymer vesicle, characterized in that: Is β -amino ester random copolymers are self-assembled to form polymer vesicles encapsulating sonosensitizers and interleukin-12, the β -Amino ester random copolymer is an amphiphilic polymer containing ROS responsive groups, wherein the ROS responsive groups are thioketal units, and the sonosensitizer is dihydrochlorin e6.

2. The ultrasound-self-cleaving IL-12 polymer vesicle according to claim 1, characterized in that: Said β -The mass ratio of the amino ester random copolymer to interleukin-12 is 5000:1 to 10000:1, β -The mass ratio of the amino ester random copolymer to the sonosensitizer is 15:1~40:

1.

3. The ultrasound-self-cleaving IL-12 polymer vesicle according to claim 1, characterized in that The size of the polymer vesicles is 100-200 nm.

4. The ultrasound-self-cleaving IL-12 polymer vesicle according to claim 1, characterized in that Said β -Amino ester random copolymer is obtained by addition reaction of NH2-PEG-NH2 and diacrylate monomer.

5. The ultrasound-self-cleaving IL-12 polymer vesicle according to claim 4, characterized in that The diacrylate monomer is 7,7-dimethyl-4,10-dioxo-3,11-dioxa-6,8-dithiotridecane-1,13-diacrylic acid diester.

6. The method for preparing ultrasound-self-cleaving IL-12 polymer vesicles according to claim 1, characterized in that: The β -Amino ester random copolymer and dihydrochlorin e6 are mixed in dimethyl sulfoxide, and then added into phosphate buffer containing interleukin-12 to form polymer vesicles in a self-assembly manner to obtain ultrasound-self-cleavage IL-12 polymer vesicles.

7. The method for preparing ultrasound-self-cleaving IL-12 polymer vesicles according to claim 6, characterized in that: The β -amino ester random copolymer and dihydrochlorin e6 were mixed in dimethyl sulfoxide by vortexing, and then the nano-microemulsion method was used to transfer the above β -The mixed solution of amino ester random copolymer and dihydrochlorin e6 was slowly pumped into phosphate buffer containing interleukin-12, placed on a magnetic stirrer and continued to stir and mix for a certain period of time, and then dialyzed overnight to obtain ultrasound-self-cleavage IL-12 polymer vesicles; the peristaltic pump peristaltic speed was 0.1 mL / min, the magnetic stirrer stirring time was 12h~24h, and the stirring speed was 1000 rpm / min.

8. The method for preparing ultrasound-self-cleaving IL-12 polymer vesicles according to claim 6, characterized in that: Said β -The mixing mass ratio of the amino ester random copolymer to the dihydrochlorin e6 is 10:1 to 5:1, β The mixing mass ratio of the amino ester random copolymer to interleukin-12 is 5000:1 to 10000:

1.

9. The method for preparing ultrasound-self-cleaving IL-12 polymer vesicles according to claim 8, characterized in that: Said β -Amino ester random copolymer, dihydrochlorin e6 and interleukin-12 are mixed in a mass ratio of 10000: 1000: 1, and each 5 mg β -Amino ester random copolymer corresponds to 50 μg interleukin-12, 1-2 mL DMSO and 3-5 mL phosphate buffer.

10. Use of the ultrasound-self-cleaving IL-12 polymer vesicles according to claim 1 in the preparation of tumor therapeutic drugs.